Nuformix (LSE:NFX) has reported encouraging preclinical results from an inhaled pharmacokinetic and target engagement study of NXP002, its lead development candidate for idiopathic pulmonary fibrosis, progressive pulmonary fibrosis and other progressive fibrosing interstitial lung diseases.
The study demonstrated that NXP002 could be successfully nebulised across a broad range of doses, producing substantial and dose-dependent exposure within the lungs while keeping systemic exposure relatively limited. Achieving high local concentrations with reduced exposure elsewhere in the body is an important consideration for therapies intended to be administered by inhalation over extended periods.
Nuformix said lung concentrations reached levels expected to produce pharmacological activity. The study also demonstrated attenuation of a key fibrosis biomarker in vivo, providing further evidence that NXP002 is engaging its intended biological target.
The findings allow the company to begin modelling a potential therapeutic window for NXP002, with the aim of identifying dose levels capable of delivering sufficient efficacy while maintaining an appropriate safety profile. The results also provide an important link between Nuformix’s previous ex vivo work using human lung tissue and its latest in vivo inhalation studies.
Following the positive data, Nuformix plans to advance NXP002 through additional preclinical development, including non-GLP dose-range-finding studies. These activities are intended to generate further information on dosing, efficacy and tolerability as the company builds the evidence required to support the programme’s next stages.
The results could also strengthen Nuformix’s position in discussions with potential development and commercial partners. The company expects to continue its partnering activities, including engagement with industry participants around the upcoming European Respiratory Society Congress.
Nuformix’s wider investment outlook remains constrained by its early-stage financial profile. The company currently generates no revenue and continues to record losses and negative free cash flow, leaving cash requirements and balance-sheet resources as important considerations. Technical indicators are also weak, with the shares trading below major moving averages. Valuation provides some support through a relatively low price-to-earnings measure, although this does not fully offset the risks associated with continued cash burn and limited financial resources.
More About Nuformix Plc
Nuformix plc is a UK-listed pharmaceutical development company focused on developing treatments for areas of unmet medical need, particularly fibrosis and oncology.
The company uses drug repurposing alongside its expertise in discovering, developing and patenting novel forms of existing compounds. Its approach is designed to create differentiated therapies through changes to factors such as dosage, formulation, delivery method or product presentation, with the potential to support early-stage licensing and partnership opportunities.
NXP002 is Nuformix’s lead preclinical programme and is being developed as a potential inhaled therapy for idiopathic pulmonary fibrosis, progressive pulmonary fibrosis and other progressive fibrosing interstitial lung diseases.
By targeting new indications and differentiated product profiles, Nuformix aims to establish commercially attractive development opportunities that can be advanced through partnerships with larger pharmaceutical and biotechnology companies.
Leave a Reply